1. Home
  2. SWZ vs IBIO Comparison

SWZ vs IBIO Comparison

Compare SWZ & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Swiss Helvetia Fund Inc. (The)

SWZ

Swiss Helvetia Fund Inc. (The)

HOLD

Current Price

$5.90

Market Cap

76.6M

Sector

Finance

ML Signal

HOLD

Logo iBio Inc.

IBIO

iBio Inc.

HOLD

Current Price

$2.07

Market Cap

84.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SWZ
IBIO
Founded
1986
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
76.6M
84.6M
IPO Year
N/A
2009

Fundamental Metrics

Financial Performance
Metric
SWZ
IBIO
Price
$5.90
$2.07
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$4.75
AVG Volume (30 Days)
68.1K
970.4K
Earning Date
01-01-0001
05-01-2026
Dividend Yield
6.59%
N/A
EPS Growth
N/A
73.08
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.84
$0.56
52 Week High
$9.43
$4.86

Technical Indicators

Market Signals
Indicator
SWZ
IBIO
Relative Strength Index (RSI) 36.89 36.94
Support Level $5.88 $2.02
Resistance Level $6.10 $2.82
Average True Range (ATR) 0.07 0.23
MACD -0.01 -0.07
Stochastic Oscillator 14.29 9.70

Price Performance

Historical Comparison
SWZ
IBIO

About SWZ Swiss Helvetia Fund Inc. (The)

Swiss Helvetia Fund Inc is a non-diversified, closed-end investment company. Its investment objective is to seek long-term capital appreciation through investment in equity and equity-linked securities of Swiss companies. The group invests in various sectors such as pharmaceuticals, food and beverage, industrial goods and services, banks, personal and household goods, construction and materials, biotechnology, medical equipment, chemicals, technology, financial services, insurance, Semiconductors, Information Technology, and retail.

About IBIO iBio Inc.

iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.

Share on Social Networks: